Primary Hyperoxaluria Type 1
Oct 09, 2023
Can Novo’s Rivfloza Outperform Its Rival Alnylam’s Oxlumo in Primary Hyperoxaluria Treatment Space?
In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a trea...
Read More...
Oct 03, 2023
AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers
AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...
Read More...
Jun 09, 2020
Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL
Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
